Discovery of a Novel EGFR PROTAC Degrader against C797S Resistance Mutation with Potent Antitumor Efficacy in NSCLC Treatment.

C797S mutation is the predominant resistance mechanism for the third-generation EGFR inhibitor osimertinib in nonsmall cell lung cancer (NSCLC). To overcome this drug resistance, a novel class of EGFR PROTAC degraders was developed in human NSCLC models. was identified as the lead compound, demonstrating potent degradation of EGFR and other main EGFR mutants (DC = 2.9 ± 1.1 nM, = 93.1 ± 6.5%). It exhibited good selectivity for degradation over EGFR. Additionally, induced cell cycle arrest and apoptosis. Mechanistic studies revealed that selectively induced EGFR degradation through a VHL and proteasome-dependent manner and downregulated EGFR-associated transcriptome. In NSCLC (EGFR) xenograft mouse models, significantly inhibited tumor growth (74.7% TGI @ 50 mg/kg) and effectively depleted EGFR proteins in tumor tissue. These findings suggest that is a potent and selective EGFR PROTAC degrader with potential for the treatment of EGFR mutant-driven NSCLC.